387 related articles for article (PubMed ID: 31086947)
1. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
Qiao YL; Wu T; Li RC; Hu YM; Wei LH; Li CG; Chen W; Huang SJ; Zhao FH; Li MQ; Pan QJ; Zhang X; Li Q; Hong Y; Zhao C; Zhang WH; Li YP; Chu K; Li M; Jiang YF; Li J; Zhao H; Lin ZJ; Cui XL; Liu WY; Li CH; Guo DP; Ke LD; Wu X; Tang J; Gao GQ; Li BY; Zhao B; Zheng FX; Dai CH; Guo M; Zhao J; Su YY; Wang JZ; Zhu FC; Li SW; Pan HR; Li YM; Zhang J; Xia NS
J Natl Cancer Inst; 2020 Feb; 112(2):145-153. PubMed ID: 31086947
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Wheeler CM; Skinner SR; Del Rosario-Raymundo MR; Garland SM; Chatterjee A; Lazcano-Ponce E; Salmerón J; McNeil S; Stapleton JT; Bouchard C; Martens MG; Money DM; Quek SC; Romanowski B; Vallejos CS; Ter Harmsel B; Prilepskaya V; Fong KL; Kitchener H; Minkina G; Lim YKT; Stoney T; Chakhtoura N; Cruickshank ME; Savicheva A; da Silva DP; Ferguson M; Molijn AC; Quint WGV; Hardt K; Descamps D; Suryakiran PV; Karkada N; Geeraerts B; Dubin G; Struyf F;
Lancet Infect Dis; 2016 Oct; 16(10):1154-1168. PubMed ID: 27373900
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Zhao FH; Wu T; Hu YM; Wei LH; Li MQ; Huang WJ; Chen W; Huang SJ; Pan QJ; Zhang X; Hong Y; Zhao C; Li Q; Chu K; Jiang YF; Li MZ; Tang J; Li CH; Guo DP; Ke LD; Wu X; Yao XM; Nie JH; Lin BZ; Zhao YQ; Guo M; Zhao J; Zheng FZ; Xu XQ; Su YY; Zhang QF; Sun G; Zhu FC; Li SW; Li YM; Pan HR; Zhang J; Qiao YL; Xia NS
Lancet Infect Dis; 2022 Dec; 22(12):1756-1768. PubMed ID: 36037823
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
Hu YM; Guo M; Li CG; Chu K; He WG; Zhang J; Gu JX; Li J; Zhao H; Wu XH; Lin B; Lin ZJ; Yao XM; Li YF; Wei F; Huang Y; Su YY; Zhu FC; Huang SJ; Pan HR; Wu T; Zhang J; Xia NS
Sci China Life Sci; 2020 Apr; 63(4):582-591. PubMed ID: 31231780
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
13. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
17. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages.
Chen Q; Zhao H; Yao X; Lin Z; Li J; Lin B; Wang R; Huang Y; Su Y; Wu T; Li C; Pan H; Huang S; Zhang J; Xia N
Vaccine; 2020 Sep; 38(39):6096-6102. PubMed ID: 32718817
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2017 Jan; 6(1):12-25. PubMed ID: 27998015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
